Synergy Innovation "Neurobiogen's New Drug Candidate 'KDS2010' Registered for Patent in China"

[Asia Economy Reporter Hyunseok Yoo] Synergy Innovation, a bio and medical device specialized company, announced on the 24th that Neurobiogen's new drug candidate 'KDS2010' has been granted a patent registration decision in China.

With this patent registration decision, Neurobiogen has secured rights in China for all neurodegenerative diseases including Alzheimer's dementia, Parkinson's, epilepsy, depression, as well as obesity. China is the world's second-largest pharmaceutical market, with a market size of approximately 150 trillion KRW.

Neurobiogen has completed patent registrations in 14 countries including China and is currently proceeding with patent registrations for the Brazilian and Indian markets.

A company official stated, "We recently completed non-clinical trials for Phase 1 clinical trial approval and are accelerating preparations to conduct clinical trials in the first half of next year." He added, "In addition to Alzheimer's disease, the main therapeutic mechanism, we will expand indications to stroke, spinal cord injury, and obesity."

Meanwhile, Synergy Innovation made an investment in convertible bonds (CB) of Neurobiogen in November 2019 to establish a new drug development pipeline and secure new growth engines, and will secure the status of the largest shareholder upon CB conversion.

This content was produced with the assistance of AI translation services.